Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Methotrexate for CNS Prophylaxis in High Risk DLBCL
NCT05054426Phase 3Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2021
- Primary completion
- Oct 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: 2 year CNS relapse rate. Status: unknown.
02
Drugs
methotrexate
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05054426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05054426.